Suscribirse

Association Between COVID-19 Infection and Pulmonary Fibrosis: A Nested Case-Control Study - 20/10/23

Doi : 10.1016/j.amjmed.2023.07.020 
Ronza Najjar-Debbiny, MD a, b, , Ofra Barnett-Griness, PhD c, d, Johad Khoury, MD e, f, Naomi Gronich, MD b, d, Gabriel Weber, MD b, g, Yochay Adir, MD b, e, Michal Shteinberg, MD, PhD b, e, Sonia Shneir, MD b, e, Lokesh Sharma f, Walid Saliba, MD, MPH b, d, h,
a Infection Control and Prevention Unit, Lady Davis Carmel Medical Center, Haifa, Israel 
b Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel 
c Statistical Unit, Lady Davis Carmel Medical Center, Haifa, Israel 
d Department of Community Medicine and Epidemiology, Lady Davis Carmel Medical Center, Haifa, Israel 
e Pulmonology Division, Lady Davis Carmel Medical Center, Haifa, Israel 
f Section of Pulmonary, Critical Care and Sleep Medicine, Yale School of Medicine, New Haven, Conn 
g Infectious Diseases Unit, Lady Davis Carmel Medical Center, Haifa, Israel 
h Translational Epidemiology Unit and Research Authority, Lady Davis Carmel Medical Center, Haifa, Israel 

Requests for reprints should be addressed to Ronza Najjar-Debbiny, MD, Infection Control and Prevention Unit, Lady Davis Carmel Medical Center, 7 Michal St, Haifa, Israel.Infection Control and Prevention UnitLady Davis Carmel Medical Center7 Michal StHaifaIsrael⁎⁎Requests for reprints should be addressed to Walid Saliba, MD, MPH, Department of Community Medicine and Epidemiology, Lady Davis Carmel Medical Center, 7 Michal St, Haifa, Israel.Department of Community Medicine and EpidemiologyLady Davis Carmel Medical Center7 Michal StHaifaIsrael

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.

Conéctese para beneficiarse!

Abstract

Background

Pulmonary fibrosis is associated with significant morbidity. Data are scarce on the link between coronavirus disease (COVID-19) and pulmonary fibrosis. We aimed to assess the association between COVID-19 with pulmonary fibrosis.

Methods

We conducted a nested case-control study in a cohort of 2,894,801 adults without a diagnosis of pulmonary fibrosis. The underlying cohort consisted of members of the largest healthcare provider in Israel aged 18 years or older as of May 1, 2020. Subjects were followed up from cohort entry until June 30, 2022, for the occurrence of pulmonary fibrosis. Ten randomly selected controls were matched to each case of pulmonary fibrosis on age, sex, and calendar time. To account for surveillance bias a lag time of 60 days was used for ascertainment of prior COVID-19 and COVID-19 severity.

Results

During follow-up 1284 patients were newly diagnosed with pulmonary fibrosis and matched with 12,840 controls. Multivariable conditional logistic-regression models showed that the odds ratio for pulmonary fibrosis was 1.80 (95% confidence interval, 1.47-2.19) in patients with COVID-19 compared with no COVID-19. The multivariable odds ratio for pulmonary fibrosis was 1.33 (1.06-1.68), 2.98 (1.16-7.65), and 9.30 (5.77-14.98) for mild, moderate, and severe COVID-19, respectively, compared with no COVID-19. The magnitude of the association was attenuated but remained statistically significant for severe disease when the lag time was extended to 180 days (1.08 [0.78-1.49], 2.37 [0.75-7.46], and 5.34 [2.75-10.36] for mild, moderate, and severe COVID-19, respectively).

Conclusions

COVID-19 appears to be associated with an increased risk of pulmonary fibrosis and the magnitude of the association increases with COVID-19 severity.

El texto completo de este artículo está disponible en PDF.

Keywords : COVID-19, Pulmonary fibrosis, SARS-CoV-2, Surveillance bias


Esquema


 Funding: None.
 Conflict of Interest: None.
 Authorship: All authors had access to the data and a role in writing this manuscript.


© 2023  Publicado por Elsevier Masson SAS.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 136 - N° 11

P. 1087 - novembre 2023 Regresar al número
Artículo precedente Artículo precedente
  • Prevalence of Heart Failure Stages in a Universal Health Care System: The Military Health System Experience
  • Véronique L. Roger, Amanda Banaag, Jessica Korona-Bailey, Tiffany M. Powell Wiley, Clesson E. Turner, Mark C. Haigney, Tracey Perez Koehlmoos
| Artículo siguiente Artículo siguiente
  • History of Migraine and Risk of COVID-19: A Cohort Study
  • Pamela M. Rist, Julie E. Buring, JoAnn E. Manson, Howard D. Sesso, Tobias Kurth

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.